Article
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Aug 2021
Alva Ajjai S, Mangat Pam K, Garrett-Mayer Elizabeth, Halabi Susan, Hansra Damien, Calfa Carmen J, Khalil Maged F, Ahn Eugene R, Cannon Timothy L, Crilley Pamela, Fisher Julie G, Haslem Derrick S, Shrestha Sagun, Antonelli Kaitlyn R, Butler Nicole L, Warren Sasha L, Rygiel Andrew L, Ranasinghe Shamika, Bruinooge Suanna S, Schilsky Richard L
Abstract excerpt
PURPOSE: The TAPUR Study is a phase II basket trial that aims to identify signals of antitumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known to be drug targets. Results in a cohort of patients with metastatic breast cancer (mBC) with high tumor mutational burden (HTMB) treated with pembrolizumab are reported. METHODS: Patients with...
Topics
Join the communities discussing this publication.